We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New portfolio company Deakin Bio-Hybrid Materials

23 Oct 2023 07:00

RNS Number : 8822Q
Frontier IP Group plc
23 October 2023
 

Reach - a non-regulatory announcement

AIM: FIPP

23 October 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - new portfolio company Deakin Bio-Hybrid Materials

 

Frontier IP, a specialist in commercialising intellectual property, today announces it has taken a 32.8 per cent equity stake in Deakin Bio-Hybrid Materials Limited, ("DeakinBio" or the "Company").

 

DeakinBio has developed a technology, termed BioSintering®, to produce advanced bio-based materials from organic waste such as chickpea broth or algae, along with widely available inorganic powders such as crushed limestone. The bio-based materials have compositions similar to natural materials such as seashells and pearl. Initial applications are as sustainable alternatives to ceramic tiles, with the potential to reduce the carbon footprint of tile manufacture by up to 90 per cent.

 

Traditional ceramic tiles have a high carbon footprint because they need to be fired at high temperatures to harden (sinter) and glaze the products. Making one square metre of tiles can emit up to 16 kg of carbon dioxide. DeakinBio's BioSintering and BioGlazing processes remove the need for firing and glazing, and the ambition is to produce tiles with similar strength and functionality to their conventional equivalents but with a much lower carbon footprint - currently calculated at 0.92 kg of CO2e emissions per square metre according to an independent Life Cycle Assessment. It is intended to make the tiles on industry-standard production lines.

 

BioSintering® and BioGlazing have been used to date to make materials based on the principles of combining biopolymers, water, and calcium carbonate particles to produce a biocomposite material after undergoing low-temperature processing. The inorganic material is currently powdered limestone, although DeakinBio is exploring the use of crushed seashells, a waste product from the seafood industry, as a source of calcium carbonate in the future.

 

The Company's first material, Fabalith®, combines calcium carbonate with a binder made from chickpea broth, a waste product from the food industry.

 

DeakinBio was founded in June 2021 by BioSintering® and BioGlazing inventor Dr Aled Roberts who is based at the Manchester Institute of Biotechnology, University of Manchester where he is a Research Fellow. Dr Roberts holds a PhD in Materials Chemistry from the University of Liverpool. He was lead researcher on the project to create StarCrete® - a new concrete-like material made from extra-terrestrial dust, potato starch and a pinch of salt, which could one day be used to build infrastructure in space.

 

The Company is also exploring the feasibility of new materials made from bio-manufacturing waste streams, such as microbial waste, after winning a £92,364 grant from Innovate UK.

 

DeakinBio won the £50,000 first prize in the University of Manchester's Eli Harari Graphene Enterprise Awards for 2022.

 

With its focus on developing new materials, partly made from organic waste streams, DeakinBio fits into Frontier IP's Materials, and Food and Agritech clusters. It is expected that there will be opportunities for the Company to share expertise with other portfolio companies, including: Alusid, which has developed complementary technology for sustainable building materials using recycled industrial waste, and; Nandi Proteins, which has extensive connections in the food industry and with potential sources of chickpea waste. Alusid's first mass-produced wall tile range, Principle, has recently been launched by Topps Tiles, the UK's no. 1 tile specialist, through its retail outlets.

 

More information is available on the Company's website: https://www.deakinbio.com/

 

 

DeakinBio Founder Dr Aled Roberts said: "We are delighted to be partnering with Frontier IP to help us accelerate the commercialisation of our exciting technologies. With their proven track record of success and expertise in technology transfer, we are confident that this collaboration will help us bring our cutting-edge solutions to the market and create real-world impact."

 

Neil Crabb, Frontier IP Chief Executive Officer, said: "We are excited about the potential of DeakinBio and its novel biocomposites, not just in the tile industry, but in other sectors too. The company fits very well into our Materials, and Food and Agritech clusters and is already sharing expertise and knowledge with other companies in our portfolio. We are looking forward to working with Aled and the DeakinBio team and supporting them to future success. "

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLBDGBDDDGXD
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.